|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,528 GBX | +1.83% |
|
+1.56% | +5.40% |
| 05:11pm | European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading | MT |
| 10:20am | EU court criticizes Commission over handling of COVID vaccine contracts | RE |
Jan 10 (Reuters) - GSK plc:
* NUCALA APPROVED IN CHINA FOR USE IN SEVERE ASTHMA
* NUCALA APPROVAL BASED ON A SEPARATE PHASE III TRIAL AMONG CHINESE PATIENTS REINFORCING MEPOLIZUMAB'S EFFICACY AND SAFETY DATA Source text for Eikon: Further company coverage:
Price
|
Change
|
5d. change
|
Capi.
| ||
|---|---|---|---|---|---|
| 2,915 PTS | +0.37% | +0.21% | - | ||
| 1,528 GBX | +1.83% | +1.56% | 79.3B | ||
| 1st Jan change | Capi. | |
|---|---|---|
| +5.40% | 79.3B | |
| +56.99% | 848B | |
| +31.64% | 627B | |
| +0.03% | 363B | |
| +15.45% | 318B | |
| +12.70% | 299B | |
| +15.51% | 243B | |
| +16.72% | 225B | |
| +16.34% | 179B | |
| +4.08% | 167B |
GSK PLC 
